Background: Current evidence suggests that lean and obese patients with nonalco-
| INTRODUCTION
The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased globally, 1 paralleling the figures of obesity and type 2 diabetes. 2, 3 These three clinical conditions, also referred to as comorbidities, cluster together in the metabolic syndrome (MetS) along with cardiovascular disease (CVD). 4 Nevertheless, obesity constitutes a key determinant of awareness of liver disease due to the known risk-adverse association between obesity and NAFLD; both diseases reflect common-environmental-risk factors, including diet and lifestyle. 1 However, NAFLD can also occur in lean (nonobese) people; [5] [6] [7] the term "lean-NAFLD" is commonly used to describe this association.
The growing prevalence of NAFLD in Asia has contributed, in part, to the recognition of lean-NAFLD due to around 8%-19% of Asians with body mass index (BMI) less than 25 kg/m 2 have also been found to have NAFLD. 8 It is now clear, however, that lean-NAFLD also exists in western countries, as demonstrated in the results of the national health and nutrition examination survey III (NHANES III) that showed a prevalence of~7% of lean-NAFLD in the United States population. 9 Unfortunately, being slim (nonobese) does not necessarily mean one is healthy; in fact, being lean does not always lead to a lower risk of diabetes, 10 CVD, 11 or even NAFLD, as recently suggested. 5, 12 In a large recent meta-analysis, we demonstrated that lean and obese patients with NAFLD share a common altered metabolic and cardiovascular profile. 5 Our observations, indeed, uncovered that lean-NAFLD patients are not necessarily "healthy lean," or "free of fat" because relative to lean-non-NAFLD people, lean-NAFLD individuals showed an excess of abdominal adipose tissue, probably as the leading cause of their NAFLD. 5 Nevertheless, while the risk factors of NAFLD in lean patients have been partially clarified, 5 knowledge of the natural history of "lean-NAFLD" is not only poorly understood, but also remains controversial. In addition, the question of whether nonobese patients are protected from severe histological outcomes has not been completely elucidated. It is plausible to speculate that co-existing diseases, such as obesity and NAFLD, are prone to worsening the prognosis. However, it has not been established whether the presence of one or several of the abovementioned comorbidities contributes to NAFLD disease severity, including fibrosis. The purpose of the present meta-analysis was to provide a quantitative estimation of the magnitude of fibrosis, as well as histological features associated with the disease severity, in lean-NAFLD versus overweight/obese-NAFLD patients.
| ME TH ODS
We followed the appropriate methods for conducting a meta-analysis of observational studies (MOOSE) 13 (Table S1 ).
| Search strategy
We searched for published studies on MEDLINE (via-PubMed),
Google Scholar, and The Cochrane Library, including The Cochrane Central Register of Controlled Trials, using the following keywords and terms in the title or abstract: "lean nonalcoholic fatty liver disease" and "nonobese nonalcoholic fatty liver disease;" details on the Boolean search are disclosed in the Supplementary Material section. In addition, we checked the reference section of all retrieved articles for additional literature sources, and the PubMed link "related articles" was used to identify potentially relevant papers. The literature search included all studies published before July 2017 and we imposed no country restrictions. The authors reviewed all abstracts independently to determine the alignment with the eligibility criteria, or to establish the appropriateness of the research topic. If these criteria were met, the authors retrieved the article and reviewed it in its entirety. There were no discrepancies in this process; details on data search/collection are summarised in Figure S1 .
| Inclusion and exclusion criteria and data collection
The following inclusion criteria were considered when assessing the eligibility of the identified studies:
1. Observational studies (cross-sectional or longitudinal studies of which baseline data was retrieved) that included patients with a histologically confirmed diagnosis of NAFLD, in which comparisons between lean and overweight/obese patients were performed.
2.
A clear definition of lean and non-lean (overweight / obese) patients with NAFLD, expressed as a BMI cut-off, which allows for the identification of two groups of patients: lean patients with NAFLD, defined as patients with a BMI ≤ 25 versus nonlean (overweight / obese) patients with NAFLD, defined as patients with BMI > 25.
3.
A clear exclusion of co-existing common chronic liver diseases and secondary causes of steatosis, including heavy alcohol consumption, total parenteral nutrition, hepatitis B and C virus infection, and the use of drugs known to precipitate steatosis.
For each study, we retrieved the following information for inclusion in the meta-analysis: (1) The following exclusion criteria were also considered when assessing the eligibility of the identified studies: (1) Studies pertaining to patients with NAFLD in which the authors failed to specify the BMI categories utilised, as explained above (lean vs non-lean); (2) duplicate publications; (3) unpublished papers (only full-text journal articles were included) and (4) papers that included data on NAFLD patients using a non-standard definition of lean subjects.
| Statistical analysis
A random effect model was adopted when summarising statistical synthesis. This model assumes that the treatment effect is not the same across all studies included in the analysis.
To specifically provide measures of the absolute difference between the mean values of the explored histological variables (fibrosis score F0-F4, NAFLD Activity Score, and steatosis score 0-3) calculated for two groups (lean vs overweight/obese) we used the difference in means. This approach was justified, as we used outcome measurements on the same scale/unit performed by the same method as described below. 14 For the dichotomous variable (NASH / non-NASH), the effect denotes odds ratio (OR) and corresponding 95% confidence interval (CI).
For each analysis, we generated a forest plot to display results;
as we hypothesised that ethnicity may provide an important source of variability, we also stratified the estimate of the average effect of the studies by ethnicity. Details regarding subgroup analyses, metaregression and heterogeneity are fully disclosed in the Supporting information. We performed all calculations using the Comprehensive Meta-Analysis computer program (BIOSTAT, Englewood, NJ, USA).
| Assessment of study quality
The quality of the studies included in the meta-analysis was assessed using The Newcastle-Ottawa Scale (NOS) (see Table S2 ).
3 | RESULTS
| Study selection
We retrieved 33 studies that were initially identified using the search strategy described in Figure S1 as potentially relevant for the present investigation. We subsequently excluded 25 studies because they did not meet the inclusion criteria: (1) in two cases, the authors used a non-conventional definition of a lean individual based on a non-standard BMI cut-off value (BMI < 30), 6, 15 and (2) 23 studies were population-based reports in which NAFLD was diagnosed noninvasively by imaging techniques or laboratory data, as we previously explained. 5 
| Study characteristics
Thus, we included the remaining eight hospital-based studies that met the inclusion criteria, 5,16-22 including a total of 2702 adultpatients of both sexes with NAFLD, in the present meta-analysis.
One study belongs to our population that took part in an earlier lean-NAFLD meta-analysis on epidemiological risk factors. 5 We obtained scores of liver fibrosis from one study through contact with the study authors, who generously provided details to calculate the pooled effect. 18 Four studies were based on a Caucasian population, 5, 16, 18, 22 whereas the remaining four included an Asian population. 17, [19] [20] [21] All the studies scored well in terms of the selection criteria, comparability of lean and overweight/obese NAFLD on the basis of the study design or analysis, and ascertainment of exposure (see Table S2 ); in all the studies, the setting was hospital-based.
There was no apparent selection bias in the indication of liver biopsy in lean or overweight/obese patients with NAFLD (Table 1); in all the studies, histological assessment was uniformly performed according to the NASH clinical research network system developed by Kleiner et al 14 The overall study characteristics, including histological variables are shown in Table 1 .
| Histological disease severity in lean versus
overweight / obese NAFLD: Being overweight / obese can raise the risk of NASH and is associated with a significant increase of the fibrosis score
The analysis of liver fibrosis, which was performed based on pooled data extracted from eight studies, 5, [16] [17] [18] [19] 21, 22 showed that overweight/obese patients (n = 2209) with NAFLD have significantly greater fibrosis scores than lean patients (n = 493) (P = .032, see Figure 1 ). Specifically, the observed difference in means between the two groups was 0.28 AE 0.13, which represents an increment of~24.82% (over pooled mean fibrosis score of 1.128 in the lean group) in the mean of fibrosis score in overweight/obese-NAFLD patients relative to the mean of fibrosis score found in lean-NAFLD. Egger's regression intercept confirmed absence of publication bias (intercept À0.34, P = .83). However, we found substantial heterogeneity (I 2 : 73.5, P = .0001) in the analysis of combined studies.
The estimate of the effect stratified by ethnicity (Asian vs Caucasian) is shown in Figure S2 ; the analysis suggests that the difference in the fibrosis score between lean and non-lean patients remained significant among Caucasians. Sub-group analysis showed that intra-group effect was homogeneous (Asian: I 2 : 58, P = .068
and Caucasian I 2 : 55, P = .083).
Although we found that the effect estimate varied among studies and the observed pooled point estimate of the difference in means ranged from 0.15 to 0.31, significant results remained after excluding one study at a time (see Figure S3 ).
We further explored the potential effect of covariate/s that could explain the observed difference in the fibrosis score between lean and overweight/obese patients. Meta-regression analysis did not reveal any significant correlation between differences in age (slope: 0.03, P = .27), HOMA-IR (slope: 0.3, P = .09), or waist circumference (slope: 0.09, P = .49) and liver fibrosis. Nevertheless, the results of meta-regression must be taken with caution because the number of studies 5, 16, 18, 19, 21 included in the analysis of clinical covariables was small.
The presence of NASH in lean versus overweight/obese patients with NAFLD was assessed based on information extracted from six studies (n = 1679) 5, 17, 18, [20] [21] [22] that reported the proportion of patients with diagnosis of NASH and non-NASH. We found that the risk of having NASH (OR 0.58 95% CI 0.34-0.97) was significantly lower in lean (n = 322) than in overweight/obese patients with NAFLD (n = 1357) (P = .04, see Figure 2 ). While no publication bias was noted (intercept 0.178, P = .92), we observed substantial and significant heterogeneity (I 2 : 66.5, P = .01).
Sub-group analysis comparing Asian vs Caucasian showed that the difference in the proportion of NASH patients in lean vs. overweight/obese remained significant among Caucasians ( Figure S4 ).
Stratification according to ethnicity showed lack of intra-group heterogeneity (Asian: I 2 : 54, P = .11 and Caucasian: I 2 : 24.7, P = .26). Figure S5 shows the impact of each study on the combined pooled effect.
Likewise, the analysis of NAFLD activity score (NAS) that was based on results from eight studies 5, [16] [17] [18] [19] [20] [21] [22] showed that lean-NAFLD patients have significantly lower mean score as compared to overweight/obese NAFLD patients (difference in means AE SE:
0.58 AE 0.16, P = .0004) ( Figure 3) ; we found no publication bias (intercept À0.68, P = .74).
We observed a significant heterogeneity (I 2 : 74.9, P = .0001) that could not be explained by ethnicity (Asian: I Figure S6 . Sub-group analysis within Asian and Caucasian showed that the difference in the NAS score between lean and overweight/obese patients was significant in both ethnic groups.
The one-study-removed analysis ( Figure S7) shows consistency of the effect across the studies, and suggests a robust association between the NAS score and the lean/ overweight-obese status.
Meta-regression analysis results suggested that HOMA-IR (slope:
0.42, P = .013), but not age (slope: 0.01, P = .8) or waist circumference (slope: 0.14, P = .58) would explain the observed difference in the NAS score, although this result should be interpreted with caution because there was limited information on clinical and biochemical co-variables to be incorporated into the analysis. us from a proper meta-regression analysis to assess the potential effect of modifiers' or covariates. Even when considering these limitations, it is worth noting that differences in HOMA-IR could account for differences in the NAFLD activity score (NAS) between the two groups which were consistent with previously reported clinical-morphological correlations. 23, 24 While there was heterogeneity in the overall results, the effects were homogeneous in the analysis stratified by ethnicity. In fact, the observed difference in the fibrosis score and NASH proportion seems to be restricted to the studies that included Caucasian population.
On the contrary, differences in the NAS score between lean and non-lean could not be explained by sub-groping analysis of the studies according to ethnicity or other relevant characteristics.
It is unlikely that either the observed heterogeneity or the differences according to ethnicity can be explained by methodological diversity, which represent variability in study design, because all the studies were hospital-based. Nevertheless, bias in the selection of patients cannot be ruled out as the reason/s of indicating the liver biopsies were not necessarily homogeneous among the studies ( Table 1) . Authors of some studies explained that liver biopsy was indicated to patients who had either persistently elevated levels of aminotransferases 17 or abnormal liver test and /or additional risk factors for NASH, including insulin resistance or MetS, 5, 18 while in other studies, authors explained that regardless of the biochemical profile, they conducted a liver biopsy on all patents with NAFLD for the purpose of diagnosing and staging of NASH. 19, 21 Furthermore, the observed heterogeneity and ethnic differences might be both attributed to variability in the participants, which is known as clinical diversity. This source of variability includes, but is not restricted to, dietary and environmental factors, and genetic predisposition. 19, 21, 25 A note of caution should be added because we included information of histological outcomes in overweight and obese individuals as a single category. Unfortunately, none of the studies but one report 20 provided data of overweight subjects as a separate group; therefore, we were unable to estimate putative differences between overweight and obese NAFLD-patients. As a remarkable aspect, none of the studies included morbid obese patients, who are known to present different histological features that would have introduced bias in the analysis of overweight/obese group; Figure S8 shows It should be also argued that NAFLD is not invariably associated with the presence of features of the metabolic syndrome. 26 The study of Akyuz and coworkers showed that hemoglobin level is an independent predictor of NASH severity not only in lean patients 16 but also NAFLD patients without obesity and insulin resistance. 26 Therefore, lean-NAFLD could represent a different clinical entity, the pathogenesis of which could be mediated by other mechanisms, for instance, microbial dysbiosis, 27 extra-hepatic underlying diseases, 28 sarcopenia, 29 or polycystic ovary syndrome with hyperandrogenism. 30 Finally, there were two studies for which the total sample size (lean-NAFLD and overweight/obese NAFLD) was small (fewer than 100 patients). 20, 22 Thus, it can be argued that smallstudy-effects might have introduced bias into the pooled analysis.
Nevertheless, no publication bias was observed in any of the assessed histological outcomes. Most importantly, we performed "conservative" random-effects analysis, which assumes that the effect sizes are heterogeneous and sampled from a distribution of population effect sizes. In addition, the one-study-removed analysis consistently demonstrated that the effect was in the same direction in all the studies, including those studies that might be regarded as underpowered ( Figures S3, S5 , and S7). For instance, the difference in means of fibrosis score between lean and overweight/obese patients with NAFLD was 0.25 AE 0.14 and 0.29 AE 0.13 in the study of Kumar 20 and Margariti, 22 respectively, which is comparable to that of the observed pooled effect (Figure 1 ).
The main strength of this study, however, stems from the relatively large sample size that was subjected to the analyses (data from 2702 patients with NAFLD in whom the disease was characterised by liver biopsy). Likewise, the magnitude and direction of the effects of all the histological outcomes were consistently noted in both, Asians and Caucasians. Interestingly, there was a remarkable uniformity in the scoring system used for the histological assessment, which was in all the studies the system developed by Kleiner et al 14 Finally, rather than using the fixed-effect model, we calculated all the effect sizes on the bases of the random-effect model, which permit generalisations that extend beyond the studies included in a systematic review. 32 It is then reasonable to speculate that an increment of~25% in the mean of fibrosis score is not negligible, but, rather, potentially imposing considerable long-term impact on the natural history of the disease. Unfortunately, among the studies included in our meta-analysis, there was only one remarkable report from Hong-Kong in which the authors performed longitudinal assessment of lean versus overweight/obese patients with NAFLD. 21 In this study, Leung et al observed a higher frequency of clinical events, including cardiovascular disease and death, in obese-NAFLD than in lean-NAFLD. 21 Therefore, whereas a greater risk of NASH and an increased mean fibrosis score among overweight/obese patients are both expected to have strong clinical impact, it should be highlighted that the studies included in our meta-analysis provided us with cross-sectional data. Hence, assessment of the long-term clinical consequences of the histological outcomes in lean versus overweight/ obese patients should be guaranteed in further prospective studies.
Whether the presence of overweight/ obesity intrinsically predicts the timing of referral to tertiary care then imposing differences in the timing of NAFLD diagnosis is not known; future longitudinal studies should also shed light on this issue.
In conclusion, the results of our cross-sectional study suggested that overweight/obese and lean-NAFLD patients while sharing all the risk factors of the MetS, 5 show differences in the histological disease severity. Overweight/obese NAFLD patients present a modest increase of overall scores of histological outcomes, including liver fibrosis, which could have substantial impact in the natural history of the disease, not to mention that relative to normal weight, obesityregardless of whether it is associated with NAFLD-is, per se, associated with significantly higher all-cause mortality. 35 This conclusion, however, should not prevent physicians from the search of NASH or SOOKOIAN AND PIROLA | 23 fibrosis in lean-NAFLD patients, particularly when presenting with visceral obesity. Lean-NAFLD patients should also be considered as potential candidates for treatment with novel therapeutic strategies aimed to reverse NASH and/or liver fibrosis, because, as demonstrated in this study, they may also present advanced disease.
